Dr. Ranjana Advani Other?
Update this Profile
Dr. Ranjana Advani Other, Hematologist (Blood Specialist)
We verify the medical license of each FindaTopDoc Verified Doctor to ensure that their license is active and they are in good medical standing.

Dr. Ranjana Advani

Oncologist | Medical Oncology

3/5(18)
875 Blake Wilbur Dr Palo Alto CA, 94304
Rating

3/5

About

Dr. Ranjana Advani is an oncologist practicing in Palo Alto, CA. Dr. Advani specializes in the care and treatment of patients with cancer. As an oncologist, Dr. Advani manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Oncologists will care for their patients throughout the course of the disease. Types of oncologists include medical oncologists, surgical oncologists, radiation oncologists, gynecologic oncologists, pediatric oncologists and hematologist oncologists.

Education and Training

Bombay University, K.J. Somaiya Medical College And Research Centre 1982

Butler University in Indianapolis

Grant Government Medical College 1982

Grant Government Medical College 1983

Board Certification

Internal MedicineAmerican Board of Internal MedicineABIM- Medical Oncology- 1995

Provider Details

FemaleEnglish 35 years of experience

Treatments

  • Lymphoma
  • Extra Corporeal Shockwave Therapy

Fellowships

  • Stanford University School of Medicine,Stanford, Ca, United States   1996

Publications

  • Leukemia & lymphomaBevacizumab and cyclosphosphamide, doxorubicin2014
  • Jourl of clinical oncologyMature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte2014
  • BloodPhase 2 study of VcR-CVAD with maintence rituximab for untreated mantle cell lymphoma2014
  • NEW ENGLAND JOURL OF MEDICINETargeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma2013
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKTargeted Therapy in Relapsed Classical Hodgkin Lymphoma2013
  • BloodPlasma Epstein-Barr virus D predicts outcome in advanced Hodgkin lymphoma2013
  • NEW ENGLAND JOURL OF MEDICINEDose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastil B-Cell Lymphoma2013
  • ANLS OF ONCOLOGYEfficacy of abbreviated Stanford V chemotherapy2013
  • BRITISH JOURL OF HAEMATOLOGYThe efficacy and tolerability of adriamycin, bleomycin2013
  • JOURL OF CLINICAL ONCOLOGYRandomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally2013
  • JOURL OF CLINICAL ONCOLOGYRisk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma2013
  • JOURL OF CLINICAL ONCOLOGYBruton Tyrosine Kise Inhibitor Ibrutinib2013
  • JOURL OF CLINICAL ONCOLOGYPhase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin2012
  • ONCOLOGISTBrentuximab Vedotin in Transplant-ive Patients with Relapsed or Refractory Hodgkin Lymphoma2012
  • JOURL OF CLINICAL ONCOLOGYBrentuximab Vedotin2012
  • LEUKEMIA & LYMPHOMACardiac toxicity associated with bevacizumab2012
  • INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICSSTAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS2011
  • CLINICAL CANCER RESEARCHMicroRs Are Independent Predictors of Outcome in Diffuse Large B2011
  • LEUKEMIA & LYMPHOMACurrent concepts and controversies in the magement of early stage Hodgkin lymphoma2011
  • Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E.Comparison of conventiol prognostic indices in patients older than 60 years with diffuse large B2010
  • EXPERT REVIEW OF ANTICANCER THERAPYRisk stratification in extranodal tural killer/T-cell lymphoma2010
  • LANCET ONCOLOGYMagement of T-cell and tural-killer-cell neoplasms in Asia2009
  • JOURL OF CLINICAL ONCOLOGYPhase I Study of the Humanized Anti2009
  • JOURL OF CLINICAL ONCOLOGYImpact of positive positron emission tomography2007
  • JOURL OF CLINICAL ONCOLOGYStage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy2004
  • BRITISH JOURL OF HAEMATOLOGYA multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era2014
  • LEUKEMIA & LYMPHOMAA multicenter phase II trial to determine the safety2013
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines2013
  • Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's lymphomas, version 1.2013.2013
  • JOURL OF CLINICAL ONCOLOGYGene Expression-Based Model Using Formalin-Fixed Paraffin2013
  • Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's Lymphomas, version 3.2012.2012
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines2012
  • PLOS ONESingle Cell Profiling of Circulating Tumor Cells2012
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKHodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines2012
  • BLOODIn situ vaccition against mycosis fungoides by intratumoral injection of a TLR92012
  • INVESTIGATIOL NEW DRUGSPhase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies2011
  • Jourl of the tiol Comprehensive Cancer NetworkHodgkin lymphoma.2011
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma2011
  • OBSTETRICS AND GYNECOLOGYLymphoma in Pregncy Initially Diagnosed as Vagil Intraepithelial Neoplasia and Lichen Planus2011
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2011
  • JOURL OF THE AMERICAN COLLEGE OF RADIOLOGYACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II2011
  • SCIENCE TRANSLATIOL MEDICINECD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma2011
  • JOURL OF CLINICAL ONCOLOGYIn Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study2010
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2010
  • Jourl of the tiol Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.2010
  • BRITISH JOURL OF HAEMATOLOGYLymphoma cell VEGFR2 expression detected2010
  • CURRENT OPINION IN ONCOLOGYThe emerging role for rituximab in the treatment of nodular lymphocyte predomint Hodgkin lymphoma2009
  • ARCHIVES OF DERMATOLOGYPrognostic Factors in Primary Cutaneous Aplastic Large Cell Lymphoma2009
  • LEUKEMIA & LYMPHOMAExtranodal tural killer/T-cell lymphoma: current concepts in biology and treatment2009
  • ONCOLOGY RESEARCHDymic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr2009
  • JOURL OF THE AMERICAN ACADEMY OF DERMATOLOGYIndolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab2008
  • Clinical advances in hematology & oncology : H&OEvaluation and magement of angioimmunoblastic T-cell lymphoma2008
  • Jourl of the tiol Comprehensive Cancer NetworkHodgkin disease/lymphoma.2008
  • Jourl of the tiol Comprehensive Cancer NetworkBeyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.2008
  • Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's lymphomas.2008
  • Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's lymphoma. Clinical practice guidelines in oncology.2006
  • Jourl of the tiol Comprehensive Cancer NetworkHodgkin disease/lymphoma. Clinical practice guidelines in oncology.2006
  • Jourl of the tiol Comprehensive Cancer NetworkMagement of advanced stage Hodgkin lymphoma.2006
  • ANLS OF ONCOLOGYA phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)2005
  • INVESTIGATIOL NEW DRUGSA phase I trial of aprinocarsen (ISIS 3521/LY900003)2005
  • Investigatiol New Drugs,A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003)2005
  • JOURL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
  • CLINICAL CANCER RESEARCHPhase I and pharmacokinetic study of BMS-188797, a new taxane alog2003
  • BloodTreatment of refractory1999
  • Leukemia & lymphomaBevacizumab and cyclosphosphamide, doxorubicin2014
  • Journal of clinical oncologyMature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte2014
  • BloodPhase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma2014
  • BloodImprovements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades2013
  • NEW ENGLAND JOURNAL OF MEDICINETargeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma2013
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKTargeted Therapy in Relapsed Classical Hodgkin Lymphoma2013
  • BloodPlasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma2013
  • NEW ENGLAND JOURNAL OF MEDICINEDose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma2013
  • ANNALS OF ONCOLOGYEfficacy of abbreviated Stanford V chemotherapy2013
  • BRITISH JOURNAL OF HAEMATOLOGYThe efficacy and tolerability of adriamycin, bleomycin2013
  • JOURNAL OF CLINICAL ONCOLOGYRandomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally2013
  • JOURNAL OF CLINICAL ONCOLOGYRisk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma2013
  • BLOODMulticenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma2013
  • JOURNAL OF CLINICAL ONCOLOGYBruton Tyrosine Kinase Inhibitor Ibrutinib2013
  • BLOODTumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma2012
  • JOURNAL OF CLINICAL ONCOLOGYPhase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin2012
  • ONCOLOGISTBrentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma2012
  • JOURNAL OF CLINICAL ONCOLOGYBrentuximab Vedotin2012
  • LEUKEMIA & LYMPHOMACardiac toxicity associated with bevacizumab2012
  • INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSSTAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS2011
  • CLINICAL CANCER RESEARCHMicroRNAs Are Independent Predictors of Outcome in Diffuse Large B2011
  • LEUKEMIA & LYMPHOMACurrent concepts and controversies in the management of early stage Hodgkin lymphoma2011
  • Hematology / the Education Program of the American Society of HematoloOptimal therapy of advanced Hodgkin lymphoma.2011
  • Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E.Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B2010
  • EXPERT REVIEW OF ANTICANCER THERAPYRisk stratification in extranodal natural killer/T-cell lymphoma2010
  • Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes2009
  • LANCET ONCOLOGYManagement of T-cell and natural-killer-cell neoplasms in Asia2009
  • JOURNAL OF CLINICAL ONCOLOGYPhase I Study of the Humanized Anti2009
  • JOURNAL OF CLINICAL ONCOLOGYImpact of positive positron emission tomography on prediction of freedom from progression after2007
  • LEUKEMIA & LYMPHOMAAngioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine2007
  • JOURNAL OF CLINICAL ONCOLOGYStage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy2004
  • Pediatric blood & cancerACR appropriateness Criteria® pediatric Hodgkin lymphoma.2014
  • BRITISH JOURNAL OF HAEMATOLOGYA multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era2014
  • ONCOLOGY-NEW YORKACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma2013
  • LEUKEMIA & LYMPHOMAA multicenter phase II trial to determine the safety2013
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines2013
  • Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's lymphomas, version 1.2013.2013
  • JOURNAL OF CLINICAL ONCOLOGYGene Expression-Based Model Using Formalin2013
  • Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's Lymphomas, version 3.2012.2012
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines2012
  • PLOS ONESingle Cell Profiling of Circulating Tumor Cells2012
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKHodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines2012
  • RADIATION ONCOLOGYInterim-treatment quantitative PET parameters predict progression2012
  • BLOODIn situ vaccination against mycosis fungoides by intratumoral injection of a TLR92012
  • CLINICAL CANCER RESEARCHA Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed2012
  • INVESTIGATIONAL NEW DRUGSPhase I trial of oblimersen (GenasenseA (R)) and gemcitabine2011
  • Journal of the National Comprehensive Cancer NetworkHodgkin lymphoma.2011
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma2011
  • BLOODPrediction of survival in diffuse large B2011
  • OBSTETRICS AND GYNECOLOGYLymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus2011
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2011
  • JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGYACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II2011
  • SCIENCE TRANSLATIONAL MEDICINECD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma2011
  • Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, Prediction of Survival In Diffuse Large B2010
  • JOURNAL OF CLINICAL ONCOLOGYIn Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study2010
  • CURRENT PROBLEMS IN CANCERACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma2010
  • CLINICAL CANCER RESEARCHVoreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed2010
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2010
  • Journal of the National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.2010
  • BLOODInterim positron emission tomography scans in diffuse large B-cell lymphoma2010
  • BRITISH JOURNAL OF HAEMATOLOGYLymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival2010
  • CURRENT OPINION IN ONCOLOGYThe emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma2009
  • ARCHIVES OF DERMATOLOGYPrognostic Factors in Primary Cutaneous Anapl2009
  • Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR)0
  • CLINICAL LYMPHOMA & MYELOMATargeting CD40 in Waldenstrom's Macroglobulinemia2009
  • LEUKEMIA & LYMPHOMAExtranodal natural killer/T-cell lymphoma: current concepts in biology and treatment2009
  • ONCOLOGY RESEARCHDynamic CD8 T-Cell Responses to Tumor2009
  • JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGYIndolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab2008
  • Clinical advances in hematology & oncology : H&OEvaluation and management of angioimmunoblastic T-cell lymphoma2008
  • Journal of the National Comprehensive Cancer NetworkHodgkin disease/lymphoma.2008
  • BLOODParaffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with2008
  • Journal of the National Comprehensive Cancer NetworkBeyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.2008
  • Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's lymphomas.2008
  • CANCERNon-Hodgkin lymphoma of the breast2007
  • CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGYTreatment of mantle cell lymphoma: Current approach and future directions2006
  • ARCHIVES OF DERMATOLOGYStaging accuracy in mycosis fungoides2006
  • Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's lymphoma. Clinical practice guidelines in oncology.2006
  • Journal of the National Comprehensive Cancer NetworkHodgkin disease/lymphoma. Clinical practice guidelines in oncology.2006
  • Journal of the National Comprehensive Cancer NetworkManagement of advanced stage Hodgkin lymphoma.2006
  • ANNALS OF ONCOLOGYA phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)2005
  • INVESTIGATIONAL NEW DRUGSA phase I trial of aprinocarsen (ISIS 3521/LY900003)2005
  • Investigational New Drugs,A phase I trial of aprinocarsen (ISIS 3521/LY900003)2005
  • JOURNAL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
  • CLINICAL CANCER RESEARCHPhase I and pharmacokinetic study of BMS-188797, a new taxane analog2003
  • Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., LitcA phase I trial of doxorubicin, paclitaxel2001
  • BloodTreatment of refractory1999

Dr. Ranjana Advani's Practice location

Practice At 875 Blake Wilbur Dr

875 Blake Wilbur Dr -
Palo Alto, CA 94304
Get Direction
New patients: 510-752-1000, 650-724-8372, 650-725-5544
Fax: 650-498-5346

Dr. Ranjana Advani's reviews

(18)
Write Review

Patient Experience with Dr. Advani


3.0

Based on 18 reviews

Dr. Ranjana Advani Other has a rating of 3 out of 5 stars based on the reviews from 18 patients. FindaTopDoc has aggregated the experiences from real patients to help give you more insights and information on how to choose the best Oncologist in your area. These reviews do not reflect a providers level of clinical care, but are a compilation of quality indicators such as bedside manner, wait time, staff friendliness, ease of appointment, and knowledge of conditions and treatments.

Recommended Articles

  • Revealing your Breast Cancer Diagnosis to Your Loved Ones

    Finding out that you have cancer is probably one of the worst things to happen to a person. The news of any illness is very discomforting news. However, the word cancer alone holds a great deal of power if you will. In terms of diseases based on common knowledge, cancer is at the top of the worst....

  • Holistic Treatments for Multiple Myeloma

    Alternative medicines for the treatment of multiple myeloma have not been discovered. However, they can assist you in managing the side effects from myeloma treatment and myeloma itself.You should consult your doctor on the following options:...

  • FDA Approves Breakthrough Gene Therapy Treatment for Lymphoma

    Researchers have been working around the clock to find new and improved treatments for different cancers. Drugs, experiments, natural remedies, and more treatment options have been heavily explored in the search for a cure. Recently a new form of treatment has been developed by researchers that...

  • Natural Compound in Garlic May Help Fight Ovarian Cancer

    Dating all the way back to 5000 years ago, garlic has been used in food and as medicine, exhibiting nutritional and medicinal value. In fact, it was the Greek physician Hippocrates, also known as the “Father of Western Medicine”, who recommended the use of garlic for a variety of conditions and...

  • The Effect of Insurance on Breast Cancer

    Early diagnosis is incredibly important in determining the chance of survival that someone with breast cancer will have. Screening and detection methods for breast cancer have made leaps and bounds over the years, but only for those people who have access to regular screening. Insurance plays a huge...

  • What Are the Symptoms of Pancreatic Cancer?

    Pancreatic cancer is one of the most common cancers in the country, and is seen in both males and females at equal rates. Based on the location in the organ, pancreatic cancer is classified into two major types – exocrine pancreatic cancer and endocrine cancer. Exocrine cancer affects the part of...

Nearby Providers

Nearest Hospitals

LUCILE SALTER PACKARD CHILDREN'S HSP AT STANFORDl

725 WELCH ROAD PALO ALTO CA 94304

Head north on Blake Wilbur Drive 413 ft
Turn right onto Welch Road 788 ft
Turn right 348 ft
Turn left 69 ft
You have arrived at your destination, on the left

STANFORD HEALTH CAREl

300 PASTEUR DRIVE STANFORD CA 94305

Head north on Blake Wilbur Drive 440 ft
Turn left onto Welch Road 1270 ft
Turn left onto Pasteur Drive 55 ft
You have arrived at your destination, on the left

MENLO PARK SURGICAL HOSPITALl

570 WILLOW ROAD MENLO PARK CA 94025

Head north on Blake Wilbur Drive 413 ft
Turn right onto Welch Road 1607 ft
Turn left onto Quarry Road 1048 ft
Turn right onto Arboretum Road 1357 ft
Turn left onto Palm Drive 1622 ft
Continue straight onto University Avenue 851 ft
Continue onto University Avenue 3088 ft
Turn left onto Middlefield Road 2535 ft
Turn right onto Willow Road 3026 ft
Turn right 219 ft
You have arrived at your destination, on the right